Robert Malenka
Vermogen: 10 M $ op 31-05-2026
Vermogen: 10 M $ op 31-05-2026
Robert Malenka is the founder of MapLight Therapeutics, Inc., founded in 2018, where the title held is Director.
Current jobs include Deputy Director at Wu Tsai Neurosciences Institute and Member at the National Academy of Medicine (United States).
Former job includes Professor at the University of California from 1996 to 1999.
Education includes a doctorate from Stanford University School of Medicine, conferred in 1983.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 15-04-2026 | 348.138 ( 0,82% ) | 10 M $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
National Academy of Medicine (United States)
National Academy of Medicine (United States) Miscellaneous Commercial ServicesCommercial Services Operates as a professional membership organization | Corporate Officer/Principal | - |
| Bedrijven | Functie | Einde |
|---|---|---|
| MAPLIGHT THERAPEUTICS, INC. | Oprichter | 23-06-2026 |
University of California
University of California Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01-01-1999 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 4 |
|---|---|
National Academy of Medicine (United States)
National Academy of Medicine (United States) Miscellaneous Commercial ServicesCommercial Services Operates as a professional membership organization | Commercial Services |
University of California
University of California Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Stanford University School of Medicine
Stanford University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapeutics for debilitating central nervous system disorders | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau